| Literature DB >> 22146371 |
Wei Li1, Ming Zhang, Yi-Nan Zheng, Jing Li, Ying-Ping Wang, Yun-Jing Wang, Jian Gu, Ying Jin, Hui Wang, Li Chen.
Abstract
To investigate the protective effects of protopanaxadiol-type ginsenoside (PDG) and its metabolite ginsenoside M1 (G-M1) on carbon tetrachloride (CCl(4))-induced chronic liver injury in ICR mice, we carried out conversion of protopanaxadiol-type ginsenosides to ginsenoside M1 using snailase. The optimum time for the conversion was 24 h at a constant pH of 4.5 and an optimum temperature of 50 °C. The transformation products were identified by high-performance liquid chromatography and electrospray ion-mass spectrometry. Subsequently, most of PDG was decomposed and converted into G-M1 by 24 h post-reaction. During the study on hepatoprotective in a mice model of chronic liver injury, PDG or G-M1 supplement significantly ameliorated the CCl(4)-induced liver lesions, lowered the serum levels of select hepatic enzyme markers (alanine aminotransferase, ALT, and aspartate aminotransferase, AST) and malondialdehyde and increased the activity of superoxide dismutase in liver. Histopathology of the liver tissues showed that PDG and G-M1 attenuated the hepatocellular necrosis and led to reduction of inflammatory cell infiltration. Therefore, the results of this study show that PDG and G-M1 can be proposed to protect the liver against CCl(4)-induced oxidative injury in mice, and the hepatoprotective effect might be attributed to amelioration of oxidative stress.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22146371 PMCID: PMC6264268 DOI: 10.3390/molecules161210093
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Proposed bioconversion pathway of PDG to G-M1.
Figure 2HPLC analysis of the bioconversion of protopanaxadiol-type ginsenosides to G-M1. Incubation time: A, 0 h, B, 24 h.
Figure 3ESI/MS spectra of G-M1. Total ion chromatograms from 100 to 800 m/z in ESI positive mode.
Effects of PDG and G-M1 on body weight and relative organ weight in CCl4-intoxicated mice. Mean ± S.D.
| Group | Body weight (g) | Relative weight (g/g body weight, %) | ||
|---|---|---|---|---|
| Heart | Liver | Spleen | ||
| Normal control | 38.26 ± 2.15 | 0.51 ± 0.05 | 5.25 ± 0.31 | 0.42 ± 0.03 |
| CCl4 control | 37.25 ± 3.56 | 0.48 ± 0.06 | 6.98 ± 0.22 # | 0.53 ± 0.09 # |
| G-M1 + CCl4 | 39.15 ± 3.33 | 0.47 ± 0.08 | 5.78 ± 0.12 * | 0.44 ± 0.07 |
| PDG + CCl4 | 40.05 ± 4.15 | 0.50 ± 0.04 | 6.23 ± 0.52 * | 0.47 ± 0.11 |
* Significance P < 0.05, compared with CCl4 control; # Significance P < 0.05, compared with normal control group.
Figure 4Effect of PDG and G-M1 on serum ALT and AST levels in CCl4-induced liver injury in mice. PDG and G-M1 were administrated for a period of 4 weeks at dose of 300 mg/kg and 30 mg/kg, respectively. Each value is mean ± S.D. for 12 mice in each group. * Significance P < 0.05, compared with CCl4 group. # Significance P < 0.05, compared with normal control group.
Figure 5Effect of PDG and G-M1 on antioxidant enzyme (SOD) activities (A) and hepatic MDA level (B) in CCl4-induced liver injury in mice. PDG and G-M1 were administered for a period of 4 weeks at dose of 300 mg/kg and 30 mg/kg, respectively. * Significance P < 0.05, compared with CCl4 group. # Significance P < 0.05, compared with normal control group.
Figure 6Histopathology of the liver (×100). (A) Normal control; (B) Treated with CCl4; (C) Treated with CCl4 + G-M1 (30 mg/kg/day); (D) Treated with CCl4 + PDG (300 mg/kg/day). The arrow represents leukocytes with infiltration.